WO2026018268 - TREATMENT OF DIABETES AND DIABETES INDUCED CKD AND THE ASSOCIATED SYMPTOMS
National phase entry is expected:
Publication Number
WO/2026/018268
Publication Date
22.01.2026
International Application No.
PCT/IN2025/051043
International Filing Date
12.07.2025
Title **
[English]
TREATMENT OF DIABETES AND DIABETES INDUCED CKD AND THE ASSOCIATED SYMPTOMS
[French]
TRAITEMENT DU DIABÈTE ET DE LA NÉPHROPATHIE CHRONIQUE INDUITE PAR LE DIABÈTE ET DES SYMPTÔMES ASSOCIÉS
Applicants **
ZYDUS LIFESCIENCES LIMITED
Inventors
JOHARAPURKAR, Amit
KSHIRASAGAR, Samadhan
JAIN, Mukul
Priority Data
202421053555
13.07.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3164 | |
| EPO | Filing, Examination, Granting | 26843 | |
| Japan | Filing, Examination, Granting | 3018 | |
| South Korea | Filing, Examination, Granting | 3987 | |
| USA | Filing, Examination, Granting | 10540 |
Total:
47,552
Contact Us
Abstract[English]
The present invention describes synergistic compositions and combinations comprising one or more prolyl hydroxylase inhibitors or pharmaceutically acceptable salts thereof and a SGLT2 inhibitors or pharmaceutically acceptable salts thereof for the treatment of diabetes and diabetes induced CKD and the associated symptoms like anemia. Specifically, the present invention provides synergistic composition and combination of compound of formula (Ia) or its pharmaceutically acceptable salts and a SGLT2 inhibitors or pharmaceutically acceptable salts thereof for the treatment of diabetes and diabetes induced CKD and the associated symptoms like anemia. The present invention also describes the preparation of such compositions and combinations.[French]
La présente invention concerne des compositions et des combinaisons synergiques comprenant un ou plusieurs inhibiteurs de la prolyle hydroxylase ou leurs sels pharmaceutiquement acceptables et un inhibiteur du SGLT2 ou ses sels pharmaceutiquement acceptables pour le traitement du diabète et de la néphropathie chronique induite par le diabète et des symptômes associés, tels que l'anémie. Plus particulièrement, la présente invention concerne une composition synergique et une combinaison d'un composé de formule (Ia) ou de ses sels pharmaceutiquement acceptables et d'un inhibiteur du SGLT2 ou de ses sels pharmaceutiquement acceptable pour le traitement du diabète et de la néphropathie chronique induite par le diabète et des symptômes associés, tels que l'anémie. La présente invention concerne également la préparation de telles compositions et combinaisons.